T790米
奥西默替尼
医学
癌症研究
表皮生长因子受体
突变
抗药性
酪氨酸激酶抑制剂
药理学
肺癌
吉非替尼
生物
埃罗替尼
癌症
肿瘤科
内科学
遗传学
基因
作者
Shuhang Wang,Yongping Song,Delong Liu
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2016-11-10
卷期号:385: 51-54
被引量:326
标识
DOI:10.1016/j.canlet.2016.11.008
摘要
The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M positive non-small cell lung cancer (NSCLC). However, resistance develops rapidly. EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors. The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors. This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3.
科研通智能强力驱动
Strongly Powered by AbleSci AI